About this episode
A BioCentury analysis of ESMO first-in-human abstracts finds antibody-drug conjugates outnumbering every other modality, even as payload innovation lags behind target innovation. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the findings and Representative Jake Auchincloss' Faster Clinical Trials Act, which would embed trials in routine care and expand the NIH's All of Us biobank. The analysts also discuss how U.S. investors are reacting to Treasury's proposed COIN...
Comments
Rate this episode
Episode Details
- Author
- BioCentury
- Show Type
- full
- Audio Format
- audio/mpeg
